HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims

Executive Summary

NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.

You may also be interested in...



Dosing Recommendation In FAQ For Goli Nutrition’s Apple Cider Vinegar Gummy Not A Health Claim

Canadian firm also got agreement from BBB National Program’s appeals panel not to require other changes in ad claims and labeling sought in a challenged by Bragg Live.

GOLO Alleges Goli Nutrition Uses ‘Deceptive’ Claims With Trademark Too Close For Comfort

GOLO expanded its litigation from trademark infringement to allege Goli Nutrition didn’t submit evidence to support claims for its apple cider vinegar gummy supplements challenged in a review by an industry self-regulation program.

Goli Nutrition’s Apple Cider Vinegar Claims Slip On Dosage In Industry Self-Regulation Review

Goli Nutrition argues NAD should have declined to review any apple cider vinegar claims because all are challenged in pending litigation. Canadian firm disagrees with NAD findings on Bragg Live challenge and appeals to National Advertising Review Board.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel